Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Transplant rejection occurs when a patient's body does not recognize the new organ and
attacks it. Patients who have kidney transplants must take drugs to prevent transplant
rejection. Alemtuzumab is a man-made antibody used to treat certain blood disorders. The
purpose of this study is to test the safety and effectiveness of using alemtuzumab in
combination with two other drugs, sirolimus and tacrolimus, to prevent organ rejection after
kidney transplantation. This study will also test whether this combination of medications
will allow patients to eventually stop taking antirejection medications entirely.
Study hypothesis: A new strategy of immunosuppression using alemtuzumab, tacrolimus, and
sirolimus for human renal transplantation will permit a step-wise withdrawal from
immunosuppressive drugs.